Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AbbVie Foe Coherus Sways PTAB To Review Humira Patent

Executive Summary

The Patent Trial and Appeal Board of the US Patent & Trademark Office has agreed to hold a trial under its inter partes review process to consider the validity of one of AbbVie Inc.'s dosing methods patents. The challenger, Coherus BioSciences Inc., is hoping to eventually market a biosimilar of Humira in the US.


Related Content

Innovators Employ Labyrinthine Defenses To Fend Off Biosimilars
Supreme Court Outcome Unlikely To Dent IPR Popularity
BIO: Deals, Investment At Risk If IPR Course Unchanged
Humira Biosimilar Under Review: Amgen, AbbVie Tango Time
Will Supreme Court Lift 'IPR Pressure' Off Biopharma?
Amgen Fails At US Patent Board In Humira Challenge
Supreme Court Must Act Fast On IPR Questions: Petitioner
US Capitol Capsule: Patent Challenge Landscape Shifting: Inter Partes Reviews Climb


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts